Kardigan, Inc. — Q3 2026 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2026; filed November 12, 2026. Kardigan is a clinical-stage cardiovascular therapeutics company with no revenue to date. Its lead programs are Danicamtiv, Ataciguat and Tonlamarsen. Results are unaudited.
Financial results and liquidity
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $64.4 million | $49.1 million | $165.8 million | $103.8 million |
| General and administrative expense | $22.2 million | $9.9 million | $54.8 million | $38.5 million |
| Net loss | $58.6 million | $60.2 million | $230.9 million | $135.6 million |
| Net loss per share, basic and diluted | $0.64 | $4.43 | $5.22 | $10.80 |
| Net cash used in operating activities | Not separately presented for the quarter | $167.2 million | $99.3 million |
At September 30, 2026, cash and cash equivalents were $78.9 million and investments were $512.5 million, totaling $591.4 million. Working capital was $438.8 million (current assets of $484.5 million less current liabilities of $45.6 million). Total assets were $649.3 million, total liabilities $76.7 million, and accumulated deficit $512.0 million. The filing reports no borrowings; balance-sheet obligations include $12.7 million of operating lease liabilities and $29.6 million of contingent milestone liabilities. No profit margin is meaningful because the company has no revenue.
Management says existing cash, cash equivalents and investments are expected to fund operations for at least 12 months from issuance of the financial statements. The filing also says the June 2026 IPO alleviated the substantial doubt about going concern previously noted in the 2025 financial statements. Management expects continued substantial losses and states additional capital will be required in the future.
Changes versus comparable periods
- For Q3, R&D rose 31%, primarily as Danicamtiv Phase 3 activity began and Ataciguat Phase 2b continued; Tonlamarsen spending declined as an earlier trial completed. G&A increased 124%, mainly from personnel costs, including higher stock-based compensation.
- Q3 operating loss increased to $64.8 million from $59.1 million, but net loss declined modestly, helped by higher interest income and a $21.8 million gain from remeasurement of contingent milestone liabilities.
- For the first nine months, operating cash use increased by $67.8 million year over year, reflecting expanded operations and clinical development. Net loss increased 70%, with higher R&D and G&A and a $21.7 million contingent-liability remeasurement expense.
- Financing included $422.5 million of net IPO proceeds in June. The IPO issued 28.75 million shares at $16.00 per share and converted all preferred stock into common stock. Common shares outstanding were 93.6 million at September 30 and 93.6 million at November 9, 2026.
Outlook, developments and risks
- Management expects clinical data in 2027: Danicamtiv KINSHIP-DCM Phase 2b topline in Q2; Ataciguat KATALYST-AV Phase 2b and Tonlamarsen KARDINAL-ASH Phase 2 topline in the second half. These are forward-looking expectations, not reported results.
- During Q3, Danicamtiv KINSHIP-DCM Cohort 2 enrollment was completed, and enrollment in the Phase 3 portion was underway in both cohorts. The filing also reports September presentations of Danicamtiv exploratory data and extended Tonlamarsen follow-up data. It separately notes a November announcement that Ataciguat Phase 2b enrollment was complete and its primary endpoint was amended to assess aortic valve calcium at Week 48, with a Week 24 interim analysis planned.
- R&D expenses are expected to rise as the company advances its pipeline, develops the Prolaio platform, and prepares for potential regulatory and commercial activities. No product approvals or product sales are reported.
- The Prolaio acquisition milestone arrangement was amended in May 2026 to payments of up to $200 million, contingent on company valuation thresholds of $5 billion, $6 billion and $12 billion by May 2032. None had been achieved by September 30. The liability is Level 3 and sensitive to stock price, volatility and other assumptions; the CEO and CMO are among the former Prolaio stockholders eligible for payments. This related-party arrangement creates valuation and governance considerations.
- Key risks include clinical efficacy and safety uncertainty, regulatory approval and trial-enrollment risks, dependence on a limited number of third-party manufacturers, and the possibility that Prolaio’s data and analytics platform may not deliver expected efficiencies or gain regulatory acceptance. The company also identifies data privacy, cybersecurity, AI-related, intellectual-property, competition and future financing risks.
- No material legal proceedings were reported. The company reported effective disclosure controls as of September 30; management’s internal-control-over-financial-reporting evaluation is deferred under the new-public-company transition rules.
Important facts for investors to verify
- Whether the stated cash runway assumptions hold as trial spending expands, and what milestones or operating plans are included in the runway estimate.
- Actual 2027 trial readout timing, enrollment progress, endpoints and final results for Danicamtiv, Ataciguat and Tonlamarsen.
- The drivers and sensitivity of the $25.6 million contingent milestone liability, including the amended Prolaio valuation triggers and related-party payment terms.
- Future cash burn, financing needs, and potential dilution from 26.0 million outstanding options, 1.75 million warrants and other equity awards.
- Whether Prolaio platform use, data handling and third-party manufacturing arrangements meet operational, regulatory and security requirements.